April 16, 2025 09:48 AM EDT
Deals
Cell/Gene Tx

Ayr­mid miss­es dead­line for de­tailed of­fer to top pri­vate eq­ui­ty bid for blue­bird

Kyle LaHucik

Senior Reporter

A ri­val bid by Ayr­mid for blue­bird bio hasn’t crossed the fin­ish line, the biotech said, af­ter fail­ing to con­firm fi­nanc­ing by a Tues­day dead­line …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Phar­ma's wins and loss­es in Trump's sprawl­ing ex­ec­u­tive or­der on drug prices

In a blow to its obe­si­ty pipeline, Pfiz­er drops oral drug af­ter liv­er in­jury case

Ex­clu­sive: A small biotech will bring Roche's An­gel­man drug back to life

What's Pfiz­er's next move af­ter shelv­ing its oral obe­si­ty drug danuglipron?

Eli Lil­ly re­ports first Phase 3 da­ta for oral GLP-1, post­ing a win in di­a­betes

sponsored

New York-based part­ner­ship sets the stan­dard for ex­pand­ing clin­i­cal tri­al ac­cess for un­der­served and di­verse ...

A service from the Financial Times